Research Paper Volume 13, Issue 20 pp 23810—23830

CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer


Figure 4. (A) There is no statistical difference of CCR5 expression between TP53 wildtype and TP53 mutation groups in TNBC samples. (B) CCR5 expression is not associated with OS in TNBC patients with wildtype TP53. (C) Patients with high CCR5 expression have better survival in TP53 mutation TNBC samples.